anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Test system for determining the effectiveness of cosmetic agents against ageing related changes in the skin comprises a radical-producing microorganism culture growing on a nutrient medium. The microorganism used pref. belongs to the class Ascomycetes, the sub-class Pyrenomycetes, the family Sordariaceae and esp. the species Podospora anserina or Neurospora crassa. USE/ADVANTAGE - The system allows in vivo testing of cosmetic agents to assess their effect on the ageing of the skin by determn. of their effect on the propagation of radical-producing microorganisms on a nutrient medium, thus avoiding the use of test animals.
A total of 32 subjects will be enrolled in one sequence group. The investigational products (IPs) will be administered according to the treatment groups(F, AE, F+AE) assigned to on sequence group in Period 1, Period 2, and Period 3.
The present invention includes an image-enhancing agent comprising a biodegradable, water-soluble polymer, synthetic or naturally derived and having repeating hydrophilic monomeric units with amino or hydroxyl groups. This agent also includes chelating agents comprising functional groups bound to an amino or hydroxyl group of the monomeric units. These chelating agents have a formation constant for divalent or trivalent metal cations of at least about 108 at physiological temperature and pH. This image-enhancing agent is biodegradable to intermediary metabolites, excretable chelates, oligomers, monomers or combinations thereof of low toxicity. These image-enhancing agents may further comprise a paramagnetic metal ion for enhancement of the image arising from induced magnetic resonance signals. Images resulting from scanning of gamma particle emissions may be enhanced when the image-enhancing agent of the present invention comprises radioisotopic metal ions emitting gamma particles. The physical conversion of these image-enhancing agents into microspheres (or, less optimally, microaggregates) allows further internal directioning of the image-enhancing agents to organs with phagocytic capabilities. Dextran is a preferred polymer; DTPA and gadolinium are respectively preferred chelating agents and paramagnetic metal ions.
Fentanyl transdermal system contains fentanyl, an opioid agonist, for transdermal administration. The amount of fentanyl released from each system per hour is proportional to the surface area (25 mcg/hour per 10.5 cm 2). The composition per unit area of all transdermal system sizes is identical. 

The molecular weight of fentanyl base is 336.5 g/mol, and the empirical formula is C 22H 28N 2O. The n-octanol: water partition coefficient is 860:1. The pKa is 8.4. 

The chemical name is N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl) propanamide. The structural formula is:

Fentanyl transdermal system is a rectangular transparent unit comprising a release liner and two functional layers. Proceeding from the outer surface toward the surface adhering to skin, these layers are:

1) a backing layer of polyethylene terephalate film; 2) a drug-in-adhesive layer. Before use, a release liner covering the drug-in-adhesive layer is removed and discarded.
Participants will be asked to perform studies to measure resting metabolic rate and activity of brown adipose tissue or brown fat. Brown fat is different from regular "white fat" in that it produces heat and burns calories. The investigators will measure how active brown fat is at normal room temperature and after participants have been exposed to cold.

The study will last 5-6 hours. It will consist of measurements made in warm temperatures and then after a period of cold exposure. For the cold exposure part of the study, participants will be asked to wear a cooling suit for 3 hrs. Skin temperature is normally about 90º Fahrenheit. The cooling suit will adjust the water temperature until your skin temperature is about 82º Fahrenheit. The suit will cover the entire body except for the face, hands, and feet. Participants may feel cold while wearing the suit and you may shiver some, but based on past studies, any shivering should be minor.

Before and after the cooling suit is turned on, body scans will be performed using a procedure called positron emission tomography (PET). These scans do not use radiation. Before the PET scans, the investigators will infuse radioactive tracer into an arm. These tracers have a low dose of radiation and will show us where the brown fat is and how active it is. One PET scan will be performed at room temperature, and the second scan will be performed after the cooling suit has been worn for 3 hours. Two additional scans using computed tomography (CT) will be performed at end of the study. CT scans are like an x-ray, and use radiation. The radiation dose in the CT scan is much higher than the tracers. When the CT scans are combined with the PET scans, we can separate brown fat from white fat.

15 pre-menopausal women will be asked to volunteer for a follow up study. For 5 months, pre-menopausal women in this study will receive monthly injections that contain a study drug (leuprolide) that reduces estrogen to postmenopausal levels. This drug is approved by the FDA to reduce estrogen for the treatment of uterine fibroids and endometriosis, but is not approved for use in healthy women. In this study, the drug is being used to decrease hormones to determine if this reduces brown fat activity. 6 months after the first injection, these women will be asked to repeat the PET/CT studies.
<P>PROBLEM TO BE SOLVED: To provide a method and an apparatus for formulating and producing lipid vesicles, particularly lipid vesicles for encapsulating remedies such as nucleic acids.  <P>SOLUTION: The invention provides an apparatus and a method for producing liposomes. By providing a buffer solution in a first reservoir and a lipid solution in a second reservoir, the lipid solution which is continuously diluted with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably includes an organic solvent, such as a lower alkanol. The invention can be used for forming lipid vesicles containing encapsulated plasmid DNAs or small molecule drugs. In one embodiment, lipid vesicles are quickly prepared at low pressure, and this approach is completely scalable. In a certain preferred embodiment, the present method does not include a static mixer or exclusive extrusion equipment.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention provides application of atractylenolide I in preparing a medicament for preventing and/or treating cervical cancer, and belongs to the technical field of chemical medicaments. In particular to application of a compound shown in a formula I, or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a hydrate thereof in preparing a medicament for preventing and/or treating cervical cancer. The compound shown in the formula I is preferably atractylenolide I. The invention also provides application of the combination of the atractylenolide I and the P2X7R antagonist in preparing medicaments for preventing and/or treating cervical cancer. The research of the invention shows that the atractylenolide I has obvious inhibition effect on the proliferation of human cervical cancer cells, and the atractylenolide I can be used for preparing medicines for preventing and/or treating cervical cancer. Meanwhile, for the inhibition of SiHa cell proliferation, the combination of the atractylenolide I and the P2X7R antagonist can play a synergistic effect, and can achieve better effect of preventing and/or treating cervical cancer. 。
The present disclosure may provide a method of facilitating management of mental wellness. Further, the method may include transmitting a questionnaire information to a user device associated with a user. Further, the questionnaire information is based on a natural language. Further, the method may include receiving a response information from the user device. Further, the response information may comprise a response based on the questionnaire information. Further, the response information is based on the natural language. Further, the method may include analyzing the response information using a first machine learning model. Further, the method may include determining a mental health assessment of the user based on the analyzing of the response information. Further, the method may include identifying a therapy information for the user based on the determination of the mental health assessment of the user.
The anxiety disorders and post-traumatic stress disorder (PTSD) transdiagnostic treatment (FSET) is brief, 5-session, cognitive-behavioral intervention designed to treat symptoms associated with anxiety disorders and PTSD. The treatment is administered by lay providers (e.g., nurses) in primary care clinics in South Africa.
BACKGROUND: Conventional surgical site infection (SSI) surveillance is labour-intensive. We aimed to develop machine learning (ML) models for the surveillance of SSIs for colon surgery and to assess whether the ML could improve surveillance process efficiency.
METHODS: This study included cases who underwent colon surgery at a tertiary center between 2013 and 2014. Logistic regression and four ML algorithms including random forest (RF), gradient boosting (GB), and neural networks (NNs) with or without recursive feature elimination (RFE) were first trained on the entire cohort, and then re-trained on cases selected based on a previous rule-based algorithm. We assessed model performance based on the area under the curve (AUC), sensitivity, and positive predictive value (PPV). The estimated proportion of reduction in workload for chart review based on the ML models was evaluated and compared with the conventional method.
RESULTS: At a sensitivity of 95%, the NN with RFE using 29 variables had the best performance with an AUC of 0.963 and PPV of 21.1%. When combining both the rule-based algorithm and ML algorithms, the NN with RFE using 19 variables had a higher PPV (28.9%) than with the ML algorithm alone, which could decrease the number of cases requiring chart review by 83.9% compared with the conventional method.
CONCLUSION: We demonstrated that ML can improve the efficiency of SSI surveillance for colon surgery by decreasing the burden of chart review while providing high sensitivity. In particular, the hybrid approach of ML with a rule-based algorithm showed the best performance in terms of PPV.
Hydroxycitric acid-metal heterocyclic compounds with covalent characteristics are provided. The subject hydroxycitric acid compounds include monomeric hydroxycitric acid (HCA) compounds having a divalent metal, lactone forms thereof, and dimeric compound forms thereof. The monomeric HCA compound includes a divalent metal (X) bonded via a 5-membered ring to both the carboxylic acid and the hydroxy group of the central C2 carbon of the HCA. In addition, a monovalent metal (Y) can also be bonded to the carboxylic acid of C3 or C1, or to both C1 and C3. The subject dimeric compounds include monomeric HCA compounds linked via a second divalent metal (X) to a carboxylic acid group of each HCA unit at C3 or C1. Also provided are compositions including a monomeric HCA compound and one or more other additional compounds. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided.
Category C. Teratogenicity studies have been performed in rats and rabbits, using oral doses up to 576 and 264 mg/kg, respectively. On a weight basis, these doses are 24 and 11 times the maximum recommended human daily dose (MRHD); on a body-surface-area basis, they are 4.2 and 3.5 times the MRHD. No evidence of fetal malformation was observed. Increased resorption was seen in rats of the 576 mg/kg group. There are no adequate and well controlled studies in pregnant women. Pentoxifylline should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
GLU: ingestion of a 6% carbohydrate solution (consisting of 100 g glucose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 20% carbohydrate solution (consisting of 100 g glucose + 100 g fructose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. CSII = continuous subcutaneous insulin infusion. MDI=multiple daily injections.
Lamivudine and Zidovudine : There is no known antidote for lamivudine and zidovudine.

Lamivudine: One case of an adult ingesting 6 grams of lamivudine was reported; there were no clinical signs or symptoms noted and hematologic tests remained normal. Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine overdose event.

Zidovudine: Acute overdoses of zidovudine have been reported in pediatric patients and adults. These involved exposures up to 50 grams. The only consistent findings were nausea and vomiting. Other reported occurrences included headache, dizziness, drowsiness, lethargy, confusion, and 1 report of a grand mal seizure. Hematologic changes were transient. All patients recovered. Hemodialysis and peritoneal dialysis appear to have a negligible effect on the removal of zidovudine, while elimination of its primary metabolite, 3’-azido-3’-deoxy-5’- O-β- D-glucopyranuronosylthymidine (GZDV), is enhanced.
The Should I Screen educational website, developed by our consultant, Rafael Meza, PhD, is available at no cost, is written at an 8th grade reading level, requires 15 minutes to use, and undergoes regular updates (https://shouldiscreen.com). The goal is to increase lung screening awareness and to encourage a shared decision making visit with a provider. Sections of the website include the benefits (the reduced likelihood of dying from lung cancer) and harms (false alarms, overdiagnosis, more testing, and invasive procedures) of screening, causes of lung cancer, methods to reduce lung cancer risk, and the lung cancer risk calculator. Improvements in knowledge have been demonstrated with individuals eligible for screening.
Low concentrations of the protein kinase C activators, bryostatins 1 and 2 synergized with rBSF-1 are useful in triggering differentiation (granule enzyme expression) and CTL development in naive, resting lymph node T-cells. Bryostatin greatly enhances efficiency of rIL-2 in triggering development of in vivo primed CTL during in vitro incubation, thereby providing evidence for the use of lower concentrations of rIL-2 for in vivo tumor rejection. Both bryostatin 1 and 2, trigger cytotoxicity of CTL clones against Ag-non-bearing target cells and inhibit CTL cytotoxicity against Ag-specific target cells. Bryostatin 1 and 2 synergize with Ca<+><+> ionophores in triggering the exocytosis of cytolytic granules from CTL at very low concentrations. Because of the lack of tumor promoting activity in the bryostatins, they are useful per se as immunomodulating drugs and as potentiators for rIL-2 in adoptive immunotherapy. <CHEM> y
The dental filling process uses a substance composed of solvent (for one of the components of the filling also e.g. ethyl acetage/amyl propionate), a varnish (pref. nitrocellulose e.g. collodion) and a pigment (resin e.g. polytrifluor chlorethylene) of size 10-80 mu, interposed to form a tight adherent elastic joint between tooth and filling. After applying the substance part of the solvent is allowed to evaporate before filling. The bonding layer provides resistances to strain caused by expansion.
Participants received titrated doses of setmelanotide once daily, by SC injection during titration period for 2 - 12 weeks. Thereafter, participants continued setmelanotide at their specific therapeutic dose for an additional 10 weeks during the open label treatment period. Participants who achieved at least a 5 kg weight loss (or at least 5% weight loss if baseline body weight was \<100 kg) at the end of the open label treatment period, continued into the 8-week double-blind withdrawal period and received 4 weeks setmelanotide and 4 weeks placebo. Following the withdrawal period, participants entered open label treatment period and received setmelanotide to complete approximately 52 weeks (\~1 year) of treatment at a therapeutic dose.
DYANAVEL XR has a high potential for abuse and misuse. The use of DYANAVEL XR exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. DYANAVEL XR can be diverted for non-medical use into illicit channels or distribution [see Drug Abuse and Dependence (9.2)]. Misuse and abuse of CNS stimulants, including DYANAVEL XR, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses and or unapproved methods of administration, such as snorting or injection.

Before prescribing DYANAVEL XR, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store DYANAVEL XR in a safe place, preferably locked, and instruct patients to not give DYANAVEL XR to anyone else. Throughout DYANAVEL XR treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
The invention belongs to the technical field of Chinese herbal medicines, and discloses a composition for treating infantile habitual constipation and a preparation method and application thereof. The composition takes nourishing but not greasy as a treatment principle, and is matched with medicines for clearing heat, promoting fluid, nourishing yin, moistening dryness, removing food retention, removing food stagnation, benefiting qi and increasing fluid, so as to achieve the effects of clearing hollow viscera, clearing heat, moistening intestines and relaxing bowels. The prescription is prepared from semen Pharbitidis, radix rehmanniae, radix scrophulariae, radix Ophiopogonis, folium Nelumbinis, fructus Cannabis, cistanchis herba, cortex Magnolia officinalis, pericarpium Citri Tangerinae, fructus forsythiae, parched semen Cassiae, glycyrrhrizae radix, parched Atractylodis rhizoma, radix et rhizoma Rhei, semen Armeniacae amarum preparata, semen Sesami Niger, endothelium corneum Gigeriae Galli, semen Pruni, raphani semen and radix astragali. The whole formula is combined and played together: the actions of clearing fu-organs and purging heat, moistening intestines and relaxing bowels are achieved to achieve the effects of not damaging healthy qi, moistening but not greasy. The prescription is suitable for treating infantile habitual constipation with syndrome of internal heat accumulation and stagnation. The formula is clinically applied for many years, is adjusted by combining with the dietary structure of the children, focuses on the habits of diet and defecation, and has remarkable curative effect.
The invention discloses lactobacillus fermentum F356, lactobacillus plantarum P470 and bifidobacterium longum L556 for relieving atherosclerosis. Lactobacillus fermentum F356 accession number GDMCC No. 63664, lactobacillus plantarum P470 accession number GDMCC No. 63665, bifidobacterium longum L556 accession number GDMCC No. 63666. All three strains are not hemolytic, do not contain virulence genes and drug resistance genes, and have good safety; can reduce cholesterol in vitro; the internal and external lipid-lowering functions are realized, and the internal lipid-lowering mechanism is clear; also has atherosclerosis relieving effect. Has great application potential and value in preventing hyperlipidemia, relieving liver injury, atherosclerosis and preventing and controlling pathogenic bacteria.
An isolated nucleostemin polypeptide is disclosed herein. The nucleostemin polypeptide includes an amino acid sequence at least 85% identical to SEQ ID NO:2. In several examples, the polypeptide regulates cell differentiation, cell proliferation, or both. Nucleic acids encoding these polypeptides, vectors including the nucleic acids, and host cells transfected with these nucleic acids are also disclosed. Methods for inducing differentiation, inhibiting proliferation, and inducing senescence of a cell by altering the level of a nucleostemin polypeptide including an amino acid sequence at least 80% identical to SEQ ID NO: 2 are also disclosed. Methods for screening for agents that affect proliferation, differentiation. Or senescence of cells are also disclosed.
Examples of medical concierge are provided. In an example, a claim can be received. The claim includes data relating to services provided by the provider to a plurality of patients. The claims can be parsed to determine the provider, the plurality of patients, and the services provided. The additional information may then be retrieved. The additional information may include one of: the number of claims submitted in the past, the status of each claim, the number of complaints submitted, the status of complaints and complaints registered by the provider. Thereafter, the claims and additional information may be analyzed and categories may be determined for the provider. The category may be determined based on a behavioral model calculated for the claim and the additional information. The categories may indicate problems in the provider's behavior.
BACKGROUND: Resolvin D2 (RvD2), with an anti-inflammatory activity, harbors a neuroprotective property. Here, serum RvD2 levels were detected with an attempt to explore its prognostic implication in human acute intracerebral hemorrhage (ICH).
METHODS: In this prospective cohort study, serum RvD2 levels of 301 ICH patients, coupled with 100 heathy individuals, were gauged. All patients were randomly divided to two groups (200 patients in the study group and 101 in the validation group) in a 2:1 ratio. Change of serum RvD2 levels after ICH was investigated, and its correlations with National Institutes of Health Stroke Scale (NIHSS) scores, hematoma volume and poststroke six-month modified Rankin Scale (mRS) scores were determined using multivariate analysis. Its independent association with poor prognosis (mRS scores of 3-6) was uncovered in the study group and its prognostic predictive value was verified in the validation group.
RESULTS: The serum levels of RvD2 in patients displayed a notable decline upon admission, as compared to controls. The levels exhibited independent correlations with NIHSS scores, hematoma size and mRS scores. Alternatively, RvD2 levels had independent relation to a poor prognosis after ICH. Within the framework of restricted cubic spline analysis, RvD2 levels were linearly correlated with the likelihood of poor prognosis, even adjusting for NIHSS scores and hematoma size. In the context of receiver operating characteristic (ROC) curve analysis, serum RvD2 dramatically distinguished risk of poor prognosis, with similar predictive ability to NIHSS scores and hematoma volume. By employing subgroup analysis, the relationship between RvD2 levels and poor prognosis was not obviously influenced by other parameters, such as age, sex, hypertension, and more. The integrated model containing serum RvD2, NIHSS scores and hematoma volume was visualized on a nomogram and showed high predictive performance and clinical effectiveness for poor prognosis via multiple evaluation metrics, including the Hosmer-Lemeshow test, ROC curve analysis, calibration curve analysis and decision curve analysis. Clinical usefulness of serum RvD2 was verified in the validation group.
CONCLUSION: Serum RvD2 levels exhibit an immediate decrease post-ICH, which could be able to accurately reflect ICH severity and efficiently prognosticate poor neurological outcomes, signifying that serum RvD2 may represent an encouraging prognostic indicator in ICH.